Advancing RAS pathway targeted therapy in NF1-MPNST - effects of SHP2 and CDK4 or CDK6 inhibitors on the tumor and the tumor immune microenvironment

syn53604892

Created By NF Service nf-osi-service

program: NF-OSI
grantDOI: https://reporter.nih.gov/search/jxiS96i18UCvyGMpzGLrgg/project-details/10660326
studyName: Advancing RAS pathway targeted therapy in NF1-MPNST - effects of SHP2 and CDK4 or CDK6 inhibitors on the tumor and the tumor immune microenvironment
dataStatus: Under Embargo
initiative: Other
studyLeads: Christine Pratilas
studyStatus: Active
diseaseFocus: Neurofibromatosis type 1
grantEndDate: 1843344000000
institutions: Johns Hopkins University
fundingAgency: Other
manifestation: MPNST
embargoEndDate: 1874880000000
grantStartDate: 1686528000000
studyFileviewId: syn53604922
syn53604915
syn53604916
syn53604922
syn53604917
syn61807383
syn71997718
syn68796874
syn68796858
syn73819123
syn73819154
syn73819184
syn73819211
syn73819231
syn73819259
syn73819289
syn73819317
syn71716863
syn64586683
syn63810851
syn63810968

Advancing RAS pathway targeted therapy in NF1-MPNST - effects of SHP2 and CDK4 or CDK6 inhibitors on the tumor and the tumor immune microenvironment page is loading…